Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04303156

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Human Immunodeficiency Virus (HIV) Infection Clinical Trial

Official title:
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir (MK-8591) in Subjects With Severe Renal Impairment

Clinical Trial Summary

This study will evaluate the general tolerability and pharmacokinetics (PK) of a single 60 mg dose of MK-8591 (Islatravir) in participants with severe renal insufficiency, compared to participants in good health.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Acquired Immunodeficiency Syndrome
  • HIV Infections
  • Human Immunodeficiency Virus (HIV) Infection
Clinical Trial Details
NCT number NCT04303156
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 1
Start date June 18, 2020
Completion date October 19, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT02715700 - Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045) Phase 1
Completed NCT03667547 - Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851) Phase 4
Completed NCT01422330 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients Phase 4
Active, not recruiting NCT05452616 - Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis N/A
Completed NCT04515641 - Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030) Phase 1
Not yet recruiting NCT06430905 - Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART Phase 1
Terminated NCT02818283 - Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention N/A
Completed NCT00717067 - Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function Phase 4
Recruiting NCT04375800 - Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066) Phase 2
Completed NCT00821535 - Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers Phase 1
Completed NCT03618511 - Interventions to Improve HIV Antiretroviral Therapy Adherence N/A
Completed NCT01768182 - Folinic Acid and Vascular Reactivity in HIV N/A